Jump to main content
Jump to site search


A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples

Author affiliations

Abstract

We report a low-cost, sensitive, bead-based electrochemical immunoarray for soluble L-selectin (or CD62L protein), a potential biomarker for staging bladder cancer. We used a semi-automated modular microfluidic array with online antigen capture on superparamagnetic beads, which were subsequently delivered to a detection chamber housing multiple sensors. The assay was designed to accurately detect CD62L in diluted serum with a limit of detection (LOD) of 0.25 ng mL−1 and a dynamic range of 0.25–100 ng mL−1. The microfluidic array gave significantly better accuracy and higher sensitivity than a standard ELISA kit, which was shown to be subject to significant systematic error at high and low concentration ranges. 31 serum samples from patients with varying grades of bladder cancer and cancer-free controls were analyzed by the immunoarray and ELISA, and the CD62L levels correlated. This work establishes a new accurate assay for determining CD62L levels and highlights the potential of this protein as a biomarker for detecting locoregional progression of bladder cancer.

Graphical abstract: A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples

Back to tab navigation

Supplementary files

Publication details

The article was received on 31 Jul 2018, accepted on 29 Sep 2018 and first published on 01 Oct 2018


Article type: Paper
DOI: 10.1039/C8AN01463A
Citation: Analyst, 2018, Advance Article
  •   Request permissions

    A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples

    G. S. Phadke, J. E. Satterwhite-Warden, D. Choudhary, J. A. Taylor and J. F. Rusling, Analyst, 2018, Advance Article , DOI: 10.1039/C8AN01463A

Search articles by author

Spotlight

Advertisements